P1739: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH IBERDOMIDE PLUS DEXAMETHASONE IN A PHASE 1B/2A OPEN-LABEL DOSE ESCALATION STUDY

P1739: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH IBERDOMIDE PLUS DEXAMETHASONE IN A PHASE 1B/2A OPEN-LABEL DOSE ESCALATION STUDY

Bibliographic Details
Main Authors:	N. W. van de Donk, S. Guo, L. Shi, J. Lord-Bessen, D. Tang, L. Karlin, K. Weisel, K. Ramasamy, P. C. Abad, A. Amin, S. Amin, S. Lonial
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000849812.21433.44

Similar Items

P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: N. W. C. J van de Donk, et al.
Published: (2022-04-01)

PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Sagar Lonial, et al.
Published: (2023-08-01)

Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma
by: Amatangelo, M, et al.
Published: (2024)

Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma
by: Van Oekelen, O, et al.
Published: (2024)

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL
by: M. Amatangelo, et al.
Published: (2022-06-01)

Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial
by: Katja Weisel, et al.
Published: (2023-03-01)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Cristina Gasparetto, et al.
Published: (2021-02-01)

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
by: Andrew J. Yee, et al.
Published: (2025-03-01)

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
by: Meletios A. Dimopoulos, et al.
Published: (2015-10-01)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
by: Andrew Spencer, et al.
Published: (2018-12-01)

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
by: Philippe Moreau, et al.
Published: (2023-03-01)

Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
by: Gupta VA, et al.
Published: (2013-05-01)

HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
by: D.S. Siegel, et al.
Published: (2020-11-01)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
by: Despina Fotiou, et al.
Published: (2022-05-01)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
by: Nooka A, et al.
Published: (2013-01-01)

Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
by: Yi L, et al.
Published: (2024-11-01)

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma
by: Katja C. Weisel, et al.
Published: (2016-07-01)

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION
by: Cesar Rodriguez Valdes, et al.
Published: (2023-08-01)

Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort.
by: Nadjoua Maouche, et al.
Published: (2022-01-01)

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
by: Pralay Mukhopadhyay, et al.
Published: (2025-02-01)

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
by: Katja Weisel, et al.
Published: (2020-08-01)

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma
by: James A. Davis, et al.
Published: (2025-03-01)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Claudio Cerchione, et al.
Published: (2016-01-01)

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
by: Paul G. Richardson, et al.
Published: (2021-03-01)

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
by: Vera A. Zherebtsova, et al.
Published: (2021-07-01)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
by: Meletios A. Dimopoulos, et al.
Published: (2018-12-01)

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES
by: H. Quach, et al.
Published: (2020-11-01)

The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone
by: Hitomi Nakayama, et al.
Published: (2024-09-01)

Isatuximab, pomalidomide and dexamethasone in the treatment of relapsed/refractory multiple myeloma in real clinical practice
by: Vadim V. Ptushkin, et al.
Published: (2024-12-01)

Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
by: Maral DerSarkissian, et al.
Published: (2023-12-01)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
by: van de Donk NW, et al.
Published: (2012-08-01)

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
by: Jacob P. Laubach, et al.
Published: (2021-02-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
by: Patrizia Tosi
Published: (2013-06-01)

Efficacy of Lenalidomide plus Low-Dose Dexamethasone in Thai Patients with Relapsed and/or Refractory Multiple Myeloma
by: Chutima Kunacheewa, et al.
Published: (2021-04-01)

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
by: Zahra Goudarzi, et al.
Published: (2024-02-01)

Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
by: María Victoria Mateos, et al.
Published: (2023-02-01)